With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
IIT Kanpur team has developed computational framework to map how cell signals influence gene activity across tissues
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
Subscribe To Our Newsletter & Stay Updated
